NUAgo Therapeutics
- Biotech or pharma, therapeutic R&D
NUAgo Therapeutics is developing the first oncology platform that shuts down cancer’s survival system by design. We do not focus on specific targets, genetics, or tumor subtypes. Our single-construct short RNAs carry proprietary kill codes that silence dozens of essential survival genes simultaneously. This approach collapses the tumor’s survial network, selectively kills cancer cells, and having no effect on healthy cells and tissue.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}